*Clinical remission in the ADVOCATE study was dened as a BVAS 0 and no glucocorticoid use in previous 4 weeks.1
†A numerical improvement was seen in mental QoL.5
‡With the EQ-5D-5L index, numerical improvements were observed at Week 26, and signicant improvements were observed at Week 52 (p=0.009) in the TAVNEOS-based regimen vs GC-based regimen.5
TAVNEOS is administered as a xed dose regimen, and it is not necessary to monitor organ impairment and undertake additional analysis beyond what is needed for standard disease management. Hepatic enzymes, total bilirubin and white blood cell count must be monitored.2 Please consult the Summary of Product Characteristics for further information.
AAV, ANCA-associated vasculitis; ANCA, anti-neutrophil cytoplasmic antibody; BVAS, Birmingham Vasculitis Activity Score; EQ-5D-5L, EuroQoL-5 dimension-5 level; EULAR, European Alliance of Associations for Rheumatology; GC, glucocorticoid; GPA, granulomatosis with polyangiitis; MOA, mechanism of action; MPA, microscopic polyangiitis; QoL, quality of life.